Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New daily pill shows promise for Long-Term psoriatic arthritis control

NCT ID NCT07286058

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 4 times

Summary

This study tests the long-term safety and effectiveness of an oral drug called zasocitinib (TAK-279) in adults with active psoriatic arthritis, a condition causing joint pain and skin patches. About 1,182 participants who completed a one-year parent study will take either a lower or higher dose daily for up to two more years. Researchers will monitor side effects and measure how well the drug controls symptoms over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Zasocitinib (also called TAK-279 or NDI-034858), an oral tablet
What this could lead to
If successful, this could confirm zasocitinib as a safe, long-term daily treatment option to control psoriatic arthritis symptoms and joint damage.
What could go wrong
This is an extension study, so participants already tolerated the drug for a year. However, long-term safety data is still being collected, and rare side effects may emerge over the additional two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,182 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is \>=19 years of age. 2. The participant has completed the 52-week treatment period in one of the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002) independent of treatment assignment, and without meeting the criteria for permanent discontinuation of trial intervention defined in the parent studies. 3. The participant must be deemed by the investigator to benefit from continued or newly initiated (that is, for participants randomized to active comparator in parent study TAK-279-PsA-3001) zasocitinib therapy. Exclusion Criteria: 1. Any participant who is deemed by the investigator to be not benefiting from the trial intervention based upon lack of improvement or worsening of their symptoms in the respective parent study. 2. Any participant who met the criteria for permanent discontinuation of trial intervention defined in the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002). 3. The participant has developed any disease(s) that might confound the evaluations of benefit of zasocitinib therapy since enrollment in the respective parent study, including but not limited to rheumatoid arthritis, axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia. 4. The participant has developed evidence of a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriatic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriatic arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    78 sites in 16 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Accurate Clinical Research

    RECRUITING

    Baytown, Texas, 77521, United States

  • Advanced Rheumatology of Houston

    RECRUITING

    The Woodlands, Texas, 77382united, United States

  • CCR Ostrava s.r.o.

    RECRUITING

    Ostrava, 702 00, Czechia

  • CGM Research Trust

    RECRUITING

    Christchurch Central, 8013, New Zealand

  • Central South University - Xiangya School of Medicine - Zhuzhou Central Hospital

    RECRUITING

    Zhuzhou, Hunan, 412007, China

  • Centro Reumatologico de Caguas

    RECRUITING

    Caguas, 00725, Puerto Rico

  • Centrum Medyczne Reuma Park

    RECRUITING

    Warsaw, 02-665, Poland

  • Clinical Hospital Center Rijeka - PPDS

    RECRUITING

    Rijeka, 51000, Croatia

  • Clinical Research Centre Ltd

    RECRUITING

    Tartu, 50106Estoni, Estonia

  • Clinical Trial Center of Chung Shan Medical University Hospital

    RECRUITING

    Taichung, 408413, Taiwan

  • Denver Arthritis Clinic - Lowry

    RECRUITING

    Denver, Colorado, 80230, United States

  • Direct Helpers Research Center

    RECRUITING

    Hialeah, Florida, 33012, United States

  • ETG Warszawa Sp. z o.o.

    RECRUITING

    Warsaw, 02-677, Poland

  • First Hospital of Shanxi Medical University

    RECRUITING

    Taiyuan, Shanxi, 030001, China

  • First OC Dermatology Research Inc.

    RECRUITING

    Fountain Valley, California, 92708, United States

  • Fukuoka University Hospital

    RECRUITING

    Fukuoka, Hukuoka, 814-0180, Japan

  • FutureMeds Wroclaw

    RECRUITING

    Wroclaw, 53-673, Poland

  • GCM Medical Group, PSC

    RECRUITING

    San Juan, 00917, Puerto Rico

  • Galilee Medical Center

    RECRUITING

    Nahariya, 2210001, Israel

  • Guangzhou First People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510180, China

  • Hamburger Rheuma Forschungszentrum (HRF II) II

    RECRUITING

    Hamburg, 20095, Germany

  • Hospital Universitario Marques de Valdecilla

    RECRUITING

    Santander, Cantabria, 39008, Spain

  • INTER CLINIC Piotr Adrian Klimiuk

    RECRUITING

    Bialystok, 15-077, Poland

  • IRIS Research and Development

    RECRUITING

    Plantation, Florida, 33324, United States

  • Innomedica OU

    RECRUITING

    Tallinn, 10117, Estonia

  • Jeffrey Loomer, MD Arizona Arthritis & Rheumatology Research

    RECRUITING

    Tucson, Arizona, 85748, United States

  • Jiangxi Pingxiang People's Hospital

    RECRUITING

    Pingxiang, Jiangxi, 337055, China

  • Klein and Associates, M.D., P.A.

    RECRUITING

    Hagerstown, Maryland, 21740-6138, United States

  • Kojunkai Social Medical Corporation Daido Clinic

    RECRUITING

    Minami-ku, Nagoya-shi, Aichi-ken, 457-8511, Japan

  • Kyorin University Hospital

    RECRUITING

    Mitaka-shi, Tokyo-To, 181-8611, Japan

  • Linyi People's Hospital

    RECRUITING

    Linyi Shi, Shandong, 276000, China

  • MEDICAL Plus s.r.o.

    RECRUITING

    Uherské Hradiště, 68601, Czechia

  • MICS Centrum Medyczne Torun

    RECRUITING

    Torun, 87-100, Poland

  • MTZ Clinical Research Powered by PRATIA - PPDS

    RECRUITING

    Warsaw, 02-172, Poland

  • MediTrials OÜ

    RECRUITING

    Tartu, 50708, Estonia

  • Mie University Hospital

    RECRUITING

    Tsu, Mie, Mie-ken, 514-8507, Japan

  • NZOZ BIF-MED S.C. Arkadiusz Wawiernia, Mariola Roykiewicz, Rafal Roykiewicz

    RECRUITING

    Bytom, 41-902, Poland

  • Nagoya City University Hospital

    RECRUITING

    Nagoya, Aichi-ken, 467-8602, Japan

  • National Hospital Organization Tokyo Medical Center

    RECRUITING

    Meguro-Ku, Tokyo, 152-8902, Japan

  • Nippon Life Hospital

    RECRUITING

    Osaka, Osaka, 550-0006, Japan

  • North Estonia Medical Centre Foundation

    RECRUITING

    Tallinn, 13419, Estonia

  • Northwest Houston Arthritis Center

    RECRUITING

    Houston, Texas, 77090, United States

  • Nova Reuma Domyslawska i Rusilowicz- Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty

    RECRUITING

    Bialystok, 15707, Poland

  • Novel Research LLC

    RECRUITING

    Bellaire, Texas, 77401, United States

  • Novel Research | Abigail Neiman - Houston, TX

    RECRUITING

    Houston, Texas, 77024, United States

  • Orto klīnika

    RECRUITING

    Riga, LV-1005, Latvia

  • Paramount Medical Research & Consulting, LLC

    RECRUITING

    Middleburg Heights, Ohio, 44130, United States

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

  • Peking University Third Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100191, China

  • Porter Rheumatology Ltd

    RECRUITING

    Nelson, 7010, New Zealand

  • Praglandia

    RECRUITING

    Prague, 150 00, Czechia

  • Pratia Czech s.r.o.

    RECRUITING

    Pardubice, 53002, Czechia

  • Pratia MCM Krakow

    RECRUITING

    Krakow, 30-727, Poland

  • Pratia Poznań

    RECRUITING

    Poznan, 60-192, Poland

  • Prywatna Praktyka Lekarska Prof. dr hab. med. Pawel Hrycaj

    RECRUITING

    Poznan, 61-397, Poland

  • Purushotham & Akther Kotha MD

    RECRUITING

    La Mesa, California, 91942, United States

  • Pv Medical Services

    RECRUITING

    Zlín, 760 01, Czechia

  • R.K. Will Pty Ltd

    RECRUITING

    Victoria Park, Western Australia, 6100, Australia

  • RCMed Oddzial Sochaczew

    RECRUITING

    Sochaczew, 96-500, Poland

  • Rheuma Medicus Sp. z o.o.

    RECRUITING

    Warsaw, 02-118, Poland

  • Sasebo Chuo Hospital

    RECRUITING

    Sasebo-shi, Nagasaki, 857-1195, Japan

  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, 610072, China

  • Southwest Rheumatology Research, LLC

    RECRUITING

    Mesquite, Texas, 75150, United States

  • St. Luke's International Hospital

    RECRUITING

    Chuo-ku, Tokyo, 104-8560, Japan

  • Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research

    RECRUITING

    Hialeah, Florida, 33016, United States

  • The Cohen Medical Centers

    RECRUITING

    Thousand Oaks, California, 91360-3967, United States

  • The First Affiliated Hospital Of Bengbu Medical College

    RECRUITING

    Bengbu, Anhui, 233004, China

  • The First Affiliated Hospital of Baotou Medical College

    RECRUITING

    Baotou Shi, Inner Mongolia, 014010, China

  • Triwest Research Associates LLC

    RECRUITING

    La Mesa, California, 91942, United States

  • Twoja Przychodnia - Nowosolskie Centrum Medyczne sp. z o.o

    RECRUITING

    Nowa Sól, 67-100, Poland

  • Twoja Przychodnia - Poznanskie Centrum Medyczne Sp. z o.o.

    RECRUITING

    Poznan, 60-324, Poland

  • Twoja Przychodnia Opolskie Centrum Medyczne

    RECRUITING

    Opole, 45-819, Poland

  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)

    RECRUITING

    Wuhan, Hubei, 430022chin, China

  • Vital Medical Center

    RECRUITING

    Veszprém, 8200, Hungary

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • West Tennessee Research Institute

    RECRUITING

    Jackson, Tennessee, 38305, United States

    Contact Email: •••••@•••••

  • West Texas Clinical Research

    RECRUITING

    Lubbock, Texas, 79424, United States

  • Zdrowie Osteo Medic sc L i A Racewicz, A i J Supronik

    RECRUITING

    Bialystok, 15-351, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.